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Abstract 
Background 
Fabry disease (FD) is a rare X-linked lysosomal storage disease caused by 
mutations in the α-galactosidase A (GLA) gene causing deficiency of α-galactosidase 
A which results in progressive glycosphingolipid accumulation, especially 
globotriaosylceramide (Gb3), in body liquids and lysosomes. In a large cohort of FD 
patients, we aimed to establish genotype/phenotype relations as indicated by serum 
LysoGb3 (deacylated Gb3). 
Methods 
In 69 consecutive adult FD patients (males: n=28 (41%)) with a GLA-mutation 
confirmed diagnosis, we conducted a multidisciplinary clinical characterization during 
their routine annual examinations, and measured serum LysoGb3 levels by high-
sensitive electrospray ionization liquid chromatography tandem mass spectrometry.  
Results 
Serum levels of LysoGb3 were significantly higher in Classic compared with Later-
Onset phenotype and higher in the latter compared with controls, both in males (52 
[40-83] vs 9.5 [4.5-20] vs 0.47 [0.41-0.61]ng/ml, P<0.001) and in females (9.9 [7.9-
14] vs 4.9 [1.6-4.9] vs 0.41 [0.33-0.48]ng/ml, P<0.001), respectively. Multivariate 
linear regression analysis showed that LysoGb3 levels were independently 
associated with, serum creatinine (β=0.09, 95%CI 0.04-0.13, P<0.001) and the 
presence of cardiomyopathy (β=25, 95%CI 9.8-41, P=0.002). LysoGb3 levels were 
higher in males with frame-shift and nonsense mutations than in males with missense 
mutations (84 [72-109] vs 41 [37-52]ng/ml, P=0.002). 
Conclusion 
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LysoGb3 relates to disease severity, enzyme replacement response, and to the 
genotype severity in males. LysoGb3 supports identifying patients at risk who require 
intensive monitoring and treatment. LysoGb3 appears to be one marker of metabolic 
phenotyping of FD. 
 
 
Keywords: Fabry disease; GLA-mutation; LysoGb3; biomarker; genotype phenotype 
relation; disease severity.  
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1. Introduction 
 
Fabry disease (FD) (OMIM#301500) is an X-linked disease, resulting from the 
deficient activity of the lysosomal enzyme -galactosidase A (-Gal A) [1, 2]. The 
enzymatic defect causes the progressive accumulation of globotriaosylceramide 
(Gb3) and related glycosphingolipids in the plasma and in tissue lysosomes 
throughout the body [1]. 
There are two major phenotypes, Classic and Later-Onset [1, 3-6]. The Classic 
phenotype is more severe due to very low or absent -Gal A activity, with the typical 
early symptoms such as acroparesthesias, angiokeratoma, corneal opacities and 
hypohidrosis, particularly in males. With advancing age, the progressive deposition of 
glycosphingolipids lead to cardiomyopathy, deterioration of kidney function, and 
premature strokes [7, 8]. The Later-Onset phenotype is typically less severe with a 
significant residual -Gal A activity in males, who usually lack the early symptoms but 
present with a cardiomyopathy or chronic kidney disease in the adult age [3, 9-11]. 
The phenotypic heterogeneity can delay the correct diagnosis.  In females, -Gal A 
activity can be normal due to random X-chromosomal inactivation [12]. Even genetic 
testing can result in novel GLA variants with unknown clinical significance [13]. This 
raises questions with regard to disease onset and progression, particularly in 
asymptomatic patients identified in family screening.  
Recently, enhanced deposits of globotriaosylsphingosine (LysoGb3) have been 
shown to be a characteristic feature of FD [14]. The deacylated Gb3, LysoGb3 (also 
called LysoGl3), also known as globotriaosylsphingosine, has been reported as a 
potential diagnostic tool in both classic and uncertain cases [15]. The utility of 
LysoGb3 is still controversial, as discussed in previous studies [15, 16], due to 
concerns that LysoGb3 levels may not be strongly associated with disease 
phenotype [17].  To answer these concerns, we evaluated whether a 
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genotype/phenotype association can be established using serum LysoGb3 levels. To 
this end, we analyzed a clinical, biochemical and genetic characterization of a large 
FD patient’s cohort that was regularly monitored at a single FD center. This is the first 
study to associate LysoGb3 levels with the FD-related comorbidities and the 
genotype severity.  
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2. Methods 
2.1. Study participants and clinical work-up 
The study was conducted in accordance with the principles of the Helsinki 
Declaration. Informed consent for collecting clinical data and blood samples for 
biobanking was obtained from all patients. 
We recruited 69 consecutive adult patients (males: n=28 (41%)) at the University 
Hospital Zurich, Switzerland, between January 2014 and December 2016. All 
patients had a confirmed GLA-mutation diagnosis and presented for routine annual 
examinations at our FD center. The cohort was established in 2001 when ERT was 
approved and offered to FD patients. ERT was prescribed at the licensed dose of 
either 0.2 mg/kg body weight of recombinant agalsidase-𝛼 (Replagal) or 1 mg/kg 
body weight agalsidase-𝛽 (Fabrazyme) and given intravenously every 14 days. 
All patients had a comprehensive workup, including medical history, cardiac, renal, 
and neurological evaluations.  The occurrence of stroke or TIA (transient ischemic 
attack) was evaluated during annual examinations by asking the patient and/or using 
the medical records. Standard transthoracic 2D-echocardiography was routinely 
performed in all patients. LVMMI was calculated using the Devereux formula [18]. 
Cardiomyopathy was defined as the presence of diastolic dysfunction and/or left 
ventricular hypertrophy on echocardiography or heart MRI. 
For the present analyses, all clinical and routine laboratory results were obtained 
from the patients` medical records.  
The healthy group consisted of 13 females and 13 males aged between 17 and 69 
years. 
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2.2. Phenotyping 
The phenotyping was performed blinded to the LysoGb3 levels and as reported 
previously [5, 19].  The phenotype was classified based on the genotype. Nonsense, 
frameshift, consensus splice site and certain missense mutations encode for 0 to 1% 
residual α-Gal activity and cause Classic phenotype in males. Alternative splicing 
mutations and certain other missense mutations encode for more than 1% of normal 
α-Gal activity and cause Later-Onset phenotype in males. The phenotype was 
confirmed based on the age of symptoms onset for each mutation. For novel 
missense mutations, the phenotype was classified based on clinical symptoms and 
signs in males and by in vitro expression assays [4, 20]. 
 
2.3. LysoGb3 measurement 
For serum LysoGb3 levels, blood samples were centrifuged and serum was 
immediately frozen at −80°C for a later batch analysis. The samples were measured 
by high-sensitive electrospray ionization liquid chromatography tandem mass 
spectrometry (ESI LC-MS/MS) using an adapted method from Gold [21]. A 7-point 
serum calibrator and an internal standard for LysoGb3 quantification (covering the 
analytic range from 0-120 ng/mL; lower limit of quantification: 0.3 ng/mL), and three 
level controls (3, 30 and 100 ng/mL) for quality control were used (ARCHIMED Life 
Science GmbH, Vienna, Austria; www.archimedlife.com). Further experimental 
details on mass spectrometric conditions and sample work-up will be available upon 
request.  
 
2.4. Statistical analysis 
We used descriptive statistics for the baseline characteristics and laboratory 
parameters. Categorical variables were expressed as proportions, continuous 
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variables as means with standard deviations and medians with interquartile ranges 
(IQR). Normal distribution was assessed by Kolmogorov-Smirnov-Test. Comparisons 
between the study groups were performed using the t test, Mann–Whitney U test, the 
Chi-square or one-way analysis of variance (ANOVA) test as appropriate. 
Correlations were determined according to the method of Spearman. 
Receiver operating characteristics (ROC) procedure was used to predict the Classic 
phenotype by serum LysoGb3 levels in all FD males and females. ROC was also 
used to predict FD among FD patients and controls. 
Univariate linear regression analysis was applied to assess the association between 
serum levels of LysoGb3 and sex, phenotype as well as disease activity as reflected 
by the FD-related clinical work-up parameters. Multivariate linear regression model 
was used to evaluate which of these disease activity parameters are independently 
associated with the LysoGb3 levels after adjustment for sex and phenotype.  
Statistical analyses were performed using SPSS/PC (version 22.0; SPSS Inc., 
Chicago, IL, USA) software package. A statistical significance level of 0.05 was used. 
All hypothesis testing was two-tailed.  
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3. Results 
3.1. Baseline characteristics 
The baseline characteristics and sex of all patients are presented in Table 1. In male 
patients, serum creatinine levels were higher and cardiomyopathy more frequent than 
in female patients. All patients on renal replacement therapy were male.  
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Table 1. Baseline characteristics 
 
 All patients 
N=69 
Males 
N=28 
Females 
N=41 
P-value 
Age, years 40 [31-53] 43 [35-51] 37 [30-56] 0.62 
Phenotype n (%)    0.31 
Classic   61 (88) 23 (82) 38 (93)  
Later-Onset  9 (12) 5 (18) 4 (7)  
On ERT n (%) 52 (75) 25 (89) 27 (64) 0.02 
Serum creatinine, 
µmol/L 
123 ± 175 198 ± 258 72 ± 29 0.003 
Urine protein/creatinine 
ratio mmol/L ** 
0.06 ± 0.19 0.05 ± 0.07 0.06 ± 0.23 0.94 
On dialysis n (%) 3 (3) 3 (11) 0 (0) 0.03 
Kidney transplant n (%) 5 (7) 5 (18) 0 (0) 0.005 
Cardiomyopathy n (%) 33 (48) 18 (64) 15 (37) 0.02 
LVMMI, g/m2 103 ± 55  125 ± 62 88 ± 44 0.007 
Stroke/TIA n (%) 10 (14) 4 (14) 6 (15) 1.00 
 
* estimated according to the CKD-Epi formula 
** Patients on renal replacement excluded 
 
Plus-minus values are means ± SD. Numbers with ranges in square brackets are 
medians and interquartile ranges. 
 
Abbreviations: ERT, Enzyme Replacement Therapy; MSSI, Mainz Severity Score 
Index, LVMMI, Left Ventricular Mass Index; TIA, Transient Ischemic Attack.  
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3.2. LysoGb3 in relation to sex and phenotype 
In males and females, serum levels of LysoGb3 were significantly higher in Classic 
than in Later-Onset phenotype patients. In healthy controls, LysoGb3 levels were 
lower than in FD patients (Figure 1A and 1B).  
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Figure 1. Serum levels of LysoGb3 in males (A) and females (B) depending of 
phenotype and in comparison to healthy controls*. 
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Table legend to Figure 1A. 1 
 2 
Classic Males    
Age GLA Mutation 
Predicted Enzyme 
Protein Change  
Cumulative Dose 
Agalsidase-α, mg  
Cumulative Dose 
Agalsidase-β, mg 
Serum Lyso-Gb3 level  
(ng/ml) 
27 c.559_560delAT p.M187Vfs*6 
 
 148.02 
29 c.1147_1149del p.F383del 
 
 117.95 
50 Deletion exon 2  3591.20  115.00 
18 c.744_745delTA p.F248LfsX7 
 
6580.00 95.50 
44 c.744_745delTA p.F248LfsX8 1935.20 2124.00 92.20 
55 c.899T>A  p.L300H 1988.00 16614.00 83.00 
49 c.744_745delTA p.F248LfsX8 2407.20 408.00 74.80 
31 c.1055_1057dupCTA p.A352_M353insT 963.60  71.70 
44 c.370-2A>G Cons. Splice Site 3539.20  57.60 
30 c.679C>T p.R220X 1240.00 17236.00 57.52 
59 c.1033T>C p.S345P 5088.00  55.20 
61 c.1033T>C p.S345P 4089.60  52.31 
67 c.581C>T p.T194I 4316.80  46.10 
39 c.827G>A p.S276N 3312.00  45.60 
44 c.581C>T p.T194I 3164.00  41.00 
36 c.581C>T p.T194I 4121.60  40.40 
59 c.899T>A  p.L300H 864.00 13536.00 40.10 
51 c.581C>T p.T194I 3778.80  40.00 
23 c.125T>C p.M42T 1776.00  39.00 
40 c.370-2A>G Cons. Splice Site 3175.20  36.80 
35 c.125T>C p.M42T 3192.00  35.30 
39 c.1033T>C p.S345P 2148.80 10472.00 24.70 
47 c.613C>T p.Pro205Ser 3608.00  17.20 
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Later-Onset Males 
Age GLA Mutation 
Predicted Enzyme 
Protein Change  
Cumulative Dose 
Agalsidase-α, mg 
Cumulative Dose 
Agalsidase-β, mg 
Serum Lyso-Gb3 level  
(ng/ml) 
39 c.902G>A p.R301Q   34.30 
41 c.337T>C p.F113L 
 
1456.00 15.40 
65 c.902G>A p.R301Q 2275.20 17064.00 11.50 
44 c.902G>A p.R301Q 1776.00 8288.00 7.50 
63 c.644A>G p.N215S 1008.00  5.30 
41 c.1196G>C p.W399S 
 
 2.00 
15 
 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
Numbers with ranges in square brackets are medians and interquartile ranges10 
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Table legend to Figure 1B. 11 
 
Classic Heterozygotes 
  
Age GLA Mutation 
Predicted Enzyme 
Protein Change  
Cumulative Dose 
Agalsidase-α, mg 
Cumulative Dose 
Agalsidase-β, mg 
Serum Lyso-Gb3 level  
(ng/ml) 
68 c.581C>T p.T194I 3328.00  26.81 
35 c.1167dupT p.V390CfsX9   23.56 
48 c.365delA p.N122IfsX8 2049.60   
65 c.581C>T p.T194I 3476.00  17.80 
51 c.1033T>C p.S345P 1364.00  16.50 
68 c.1033T>C p.S345P 1531.20  16.10 
55 c.796G>T p.D266T  2100  
65 c.640-3C>G Cons. Splice Site 5149.6  14.44 
28 c.1033T>C p.S345P 907.20  13.60 
48 c.72G>A p.Y24X   13.50 
36 c.1235_1236delCT p.N122IfsX8 194.40  12.60 
63 c.581C>T p.T194I 3113.60  12.00 
35 c.901C>T p.R301X 79.20  10.70 
31 c.1055_1057dupCTA p.A352_M353insT   10.60 
25 c.1147_1149del p.F383del   10.10 
39 c.581C>T p.T194I   10.10 
17 c.1167dupT p.V390CfsX9 1356.80  10.10 
41 c.640-3C>G Cons. Splice Site 4238.00  10.00 
51 c.1167dupT p.V390CfsX9 1298.00  9.85 
37 c.581C>T p.T194I   9.70 
63 c.72G>A p.Y24X 3245.20  9.30 
56 c.796G>T p.D266T  2024.00 8.90 
62 c.744_745delTA p.F248LfsX7   8.60 
23 c.125T>C p.M42T 2360.00  8.60 
17 
 
34 c.581C>T p.T194I 3366.00  8.30 
29 c.704C>A p.Ser235Tyr 
 
 8.2 
31 c.125T>C p.M42T 2419.20  8.00 
33 c.744_745delTA p.F248LfsX7 379.60  7.90 
42 c.1033T>C p.S345P 
 
 7.80 
24 c.1167dupT p.V390CfsX9 1560.00  7.61 
29 c.125T>C p.M42T 1786.00  7.5 
26 c.125T>C p.M42T 2195.20  7.30 
23 c.1033T>C p.S345P   7.00 
32 c.581C>T p.T194I 
 
 6.10 
36 c.154T>C 
p.C52R 
  
 
5.90 
39 c.744_745delTA p.F248LfsX7 775.20 5928.00 5.20 
48 c.870G>C 
p.M290I 
 
  
.80 
 
Later-Onset Heterozygotes 
   
Age GLA Mutation 
Predicted Enzyme 
Protein Change  
Cumulative Dose 
Agalsidase-α, mg 
Cumulative Dose 
Agalsidase-β, mg 
Serum Lyso-Gb3 level  
(ng/ml) 
37 c.902G>A p.R301Q 
 
 5.20 
73 c.902G>A p.R301Q 2128.00  4.90 
33 c.337T>C p.F113L 
 
 1.6 
 12 
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There was one overlap in LysoGb3 levels between males with the Classic and Later-13 
Onset phenotypes: the male with the highest LysoGb3 level within the Later-Onset 14 
phenotype group was newly diagnosed having FD and not yet on ERT. Among the 15 
females, one Classic and three Later-Onset had similar LysoGb3 values. There was 16 
no overlap in LysoGb3 levels between FD patients and controls.  17 
The ROC curve indicated a high predictive value for LysoGb3 to identify FD patients 18 
among patients and controls: AUC=1 for each sex, with the best calculated cutoff for 19 
sensitivity and specificity at 34.8 ng/ml for males and 8.1 ng/ml for females.  20 
For prediction of the Classic versus Later-Onset phenotype among FD patients, 21 
LysoGb3 levels nearly ideally predicted the Classic phenotype in males: AUC=0.98 22 
(best calculated cutoff 43.3 ng/ml); in females, the predictive accuracy of LysoGb3 23 
levels was high:  AUC=0.81 (best calculated cutoff 9.9 ng/ml). 24 
 25 
3.3. LysoGb3 in relation to disease severity 26 
In an univariate linear regression analysis, LysoGb3 levels were associated with sex, 27 
phenotype, serum creatinine, renal replacement, LVMMI, presence of 28 
cardiomyopathy and stroke/TIA. In a multivariate linear regression analysis, if 29 
adjusted for sex and phenotype, LysoGb3 levels remained independently associated 30 
with the same parameters (Table 2).31 
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Table 2. Linear regression for serum LysoGb3 as the dependent variable. 32 
 33 
 Univariate Multivariate * 
Characteristics β (95% CI)  P Value β (95% CI)  P Value 
Sex, male 52.3 (44.2-62.4)  <0.001 n.a.  
Classic phenotype 30.6 (22.7-38.5)  <0.001 n.a.  
Age, year  0.58 (0.40-0.75)  <0.001 1.01 (0.64-1.38) <0.001 
Serum creatinine, µmol/L 0.11 (0.07-0.15)  <0.001 0.09 (0.04-0.13) <0.001 
Urin protein/creatinine ratio, mmol/L 46.8 (-4.3 to 97.8)  0.07   
Renal replacement 45.4 (21.7-69.0)  <0.001 42.2 (18.9-65.5) 0.001 
Cardiomyopathy 32.1 (19.8-44.5)  <0.001 25.5 (9.81-41.1) 0.002 
LVMMI, g/m2 0.24 (0.18-0.30)  <0.001 0.29 (0.20-0.39) <0.001 
Stroke/TIA 27.6 (5.53-49.6)  0.02 23.0 (0.93-45.1) 0.04 
 34 
*Adjusted for sex and phenotype 35 
Abbreviations: LVMMI, left-ventricular myocardial index; TIA, trans ischemic attack. 36 
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LysoGb3 levels significantly correlated with the serum creatinine (R=0.28, P=0.02), 
LVMMI (R=0.27, P=0.03) and protein/creatinine ratio (R=0.33, P=0.007). LysoGb3 
levels weekly correlated with age in females (R=0.34, R=0.03) but not in males (R=-
0.22, P=0.26).  
 
3.4. LysoGb3 in relation to genotype and between family members 
If LysoGb3 measured during the routine annual examination was available in at least 
3 family members, the levels were grouped by the family, as shown in Figure 2. 
Within one family, the LysoGb3 levels were mostly similar among males and females 
respectively and were always higher in males than in females. If LysoGb3 showed 
greater differences between the family members with the same sex, it could be partly 
associated with differences in the disease burden and whether the patient was 
treated with enzyme replacement. In detail, in Family 1, the 44-year-old male with 
LysoGb3 of 92.2 ng/ml much earlier developed end-stage renal disease and required 
kidney transplantation than did his 49-year-old brother who had LysoGb3 of 74.8 
ng/ml. The relatively high LysoGb3 level of 95.5 ng/ml of their 18-year-old 
oligosymptomatic nephew remains difficult to interpret; the phenomenon of high 
LysoGb3 levels in children and younger adults is known from the literature [22] and 
may represent an early plateau during the pre-symptomatic period, this storage 
already begins during the fetal phase [23].  In Family 2, the 68-year-old female with 
the highest LysoGb3 level of 26.8 ng/ml has the most severe phenotype among the 
females within the same family being hemiplegic due to recurrent strokes despite 
ERT. In Family 4, the 35-year-old female had a higher LysoGb3 level (23.6 ng/ml) 
than had her aunt and cousin which might be explained by the fact that she was not 
yet on ERT due to compliance reasons. Previous studies showed that LysoGb3 
decreases following ERT initiation [24]. In Family 5, the 39-year-old male with the 
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lowest LysoGb3 level of 24.7 ng/ml has a less severe phenotype with normal kidney 
function and a lower MSSI than his 59 and 61-year-old uncles who had LysoGb3 
values of 55.2 and 52.3 ng/ml and are both on renal replacement therapy.    
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Figure 2. Plasma LysoGb3 levels per family*. 
 
 
 
 
 
* Families with at least three family members were plotted 
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** Table legend to Figure 2. 
 
Nr GLA Mutation / Predicted 
Enzyme Protein Change 
Phenotype LysoGb3 Sex Age ERT 
1 c.559_560delAT / 
p.M187Vfs*6 
(6 family members) 
Classic 95.5 m 18 + 
92.2 m 44 + 
74.8 m 49 + 
8.6 f 62 - 
7.9 f 20 + 
5.2 f 39 + 
2 c.581C>T / p.T194I 
(11 family members) 
Classic 46.1 m 67 + 
41.0 m 44 + 
40.4 m 36 + 
40.0 m 51 + 
26.8 f 68 + 
17.8 f 65 + 
12.0 f 63 + 
10.1 f 39 - 
9.7 f 37 - 
8.3 f 34 + 
6.1 f 32 - 
3 c.125T>C / p.M42T 
(6 family members) 
 
 
Classic 39.0 m 23 + 
35.3 m 35 + 
8.6 f 25 + 
7.5 f 29 + 
7.3 f 26 + 
8.0 f 31 + 
4 c.1167dupT / p.V390CfsX9 
(4 family members) 
 
 
Classic 23.6 f 35 - 
10.1 f 17 + 
9.9 f 51 + 
7.6 f 24 + 
5 c.1033T>C / p.S345P 
(8 family members) 
 
 
Classic 55.2 m 59 + 
52.3 m 61 + 
24.7 m 39 + 
16.5 f 51 + 
16.1 f 68 + 
13.6 f 28 + 
7.8 f 42 - 
7.0 f 23 - 
6 c.370-2A>G / Cons. Splice Classic 57.6 m 44 + 
24 
 
Site 
(3 family members) 
 
36.8 m 40 + 
14.4 f 65 + 
7 c.902G>A / p.R301Q 
(3 family members) 
 
Later-Onset 11.5 m 65 + 
5.2 f 37 - 
4.9 f 73 + 
 
Abbreviations: ERT, Enzyme Replacement Therapy. 
 
  
25 
 
The mutations within the Classic phenotype patients were subdivided into two groups 
according to their structure and function. Group A was defined by frame-shift or 
nonsense mutations that lead to a major change in the gene products which can be 
caused by deletions, insertions, duplications and some point mutations [1]. Group B 
included missense mutations caused by individual point mutations that lead to single 
amino acid changes.  Only patients with the same ERT preparation (α-agalsidase) 
with treatment duration of at least 5 years at stable dose were included into this 
analysis in order to balance the ERT effect on the LysoGb3 levels [24]. In males, 
LysoGb3 levels were higher in group A than in group B (Figure 3). In contrast, in 
females, LysoGb3 levels did not differ significantly between group A (n= 6) and group 
B (n=13) (10.0 [8.3-15.2] vs 12.0 [8.2-16.3]; P=0.77). 
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Figure 3. Serum Lysob3 levels in affected males* according to mutation severity by 
structure and function: A frame-shift and nonsense-mutation versus B missense 
mutations. 
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*Included only males with the same ERT preparation (α-agalsidase) at a stable dose 
of at least 5 years. 
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Table legend to Figure 3.  
 
Mutations A  Mutations B 
GLA Mutation Predicted Aminoacid  Serum Lyso-
Gb3 (ng/ml) 
GLA 
Mutation 
Predicted Aminoacid Serum Lyso-
Gb3 (ng/ml) 
Deletion exon 2  115.0 c.125T>C p.M42T 39.0 
c.744_745delTA p.F248LfsX7 92.2 c.125T>C p.M42T 35.3 
c.744_745delTA p.F248LfsX7 74.8 c.581C>T p.T194I 41.0 
c.1055_1057dupCTA p.A352_M353insT 71.7 c.581C>T p.T194I 46.1 
   c.581C>T p.T194I 40.0 
   c.581C>T p.T194I 
 
40.4  
   c.899T>A 
 
p.L300H 
 
40.1 
  c.899T>A p.L300H 83.0 
  c.370-2A>G Cons. Splice Site 36.8 
  c.370-2A>G Cons. Splice Site 57.6 
  c.827G>A 
 
p.S276N 
 
45.6 
  c.1033T>C p.S345P 52.3 
  c.1033T>C 
 
p.S345P 
 
24.7 
  c.1033T>C p.S345P 55.2 
  c.613C>T 
 
p.P205S 
 
17.2 
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Discussion 
In this relatively large and well characterized cohort of genetically proven FD patients,  
serum levels of LysoGb3 were significantly higher than in the healthy controls. More 
importantly, LysoGb3 levels were significantly higher in the Classic than in the Later-
Onset phenotype in male and female patients. After adjustment for sex and 
phenotype, LysoGb3 was independently associated with the relevant co-morbidities 
such as kidney function, renal replacement therapy, cardiomyopathy, stroke and TIA.  
Within families, LysoGb3 levels were generally similar within one sex but always 
higher in males than in females. However, higher LysoGb3 levels in family members 
of the same sex were found in patients with higher disease activity, not on ERT, or at 
young age.  
Interestingly, the analysis of just the Classic phenotype, showed that serum LysoGb3 
levels were higher among the males with severe mutations, such as frame-shift or 
nonsense mutations, that are known to lead to grossly altered gene products. These 
high LysoGb3 levels may be partly interpreted as a result of particularly low or absent 
α-Gal A activities in males with such mutations resulting in accumulation of LysoGb3 
[25]. Additionally, LysoGb3 could be de-novo synthesized by sequential glycosylation 
of sphingoid bases by the action of a specific enzyme, more accelerated in males 
with “severe” mutations.  
In contrast to LysoGb3 levels in the male patients, LysoGb3 levels of female patients 
did not depend on the mutation severity which might be ascribed to the random X-
chromosomal inactivation in the heterozygous [12].  
In FD, the correct risk stratification based on an understanding of the genotype and 
phenotype relationship is an urgent though unmet clinical need. Since FD has 
become treatable with ERT [2, 26] and more recently with further treatment strategies 
[27-30], there is increasing awareness of FD among primary care physicians and 
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different specialists, and systematic screening among high-risk populations [31-33] 
and newborns [34] has become more frequent. This has resulted in increased 
detection of mutations with unknown clinical relevance [35, 36].  
The diagnosis is further complicated in females; at least 40% of the GLA-mutation 
confirmed females have normal or slightly decreased α-Gal A activities and require 
GLA sequencing to confirm heterozygosity [12, 37].  In males, the diagnosis of FD 
requires demonstrating of decreased α-Gal A activity in leucocytes; the diagnosis 
then can be confirmed by additional GLA mutation analysis. However, males with the 
Later-Onset phenotype may still have a significant residual enzyme activity. 
Consequently, male Later-Onset phenotype FD patients often lack the typical early-
onset classical manifestations, but they do show later disease manifestation and a 
predominance of single organ disease, particularly of the heart and kidney [3, 4, 9-
11]. In these patients, FD might not be recognized as the cause of heart, kidney, or 
cerebrovascular diseases. These might be misdiagnosed and ascribed to more 
common pathology including aging processes or cardiovascular risk factors [38].  
A highly sensitive and specific biomarker could fill the diagnostic gap and help avoid 
invasive biopsies and assure a swift diagnosis in patients with suspected FD. Such a 
biomarker may also improve disease staging and risk stratification as well as support 
the decision whether a patient should be started on ERT or should only be closely 
monitored.  
Previous studies identified LysoGb3 as a helpful diagnostic tool in classic and 
uncertain cases [14], and particularly in females [5].  Rombach and colleagues found 
LysoGb3 levels to be associated with white matter lesions in males, and with MSSI 
and left- ventricular mass in females [39]. Lenders and colleagues reported 
associations of LysoGb3 levels with the serum-mediated ERT inhibition [40].  
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In Later-Onset (so-called Non-classical) phenotype FD patients, Smid observed that 
LysoGb3 levels are similar in patients of the same sex and with the same GLA 
variant [16]. Our findings confirm the relation between LysoGb3 levels and Classic 
and Later-Onset phenotypes [16]. Moreover, our results show an independent 
association of LysoGb3 with the most important clinical manifestations such as renal, 
cardiac and cerebrovascular disease, and treatment response expressed by serum-
mediated ERT inhibition. Notably, our results did not show an influence of the long-
term cumulative dose of ERT on the LysoGb3 levels. This finding is in accordance 
with previous studies showing that LysoGb3 levels decrease after the ERT initiation 
and reach a plateau already after 2-3 months [24, 41]. 
Our study is the first to have analyzed LysoGb3 levels per family. It is valuable 
because family members usually have similar modifying genes and live under similar 
environmental conditions. Our data are also novel in showing a strong relation 
between LysoGb3 and mutation severity in males. The additional measurement of 
LysoGb3 may therefore augment the functional characterization of GLA mutations.         
However, previous studies [15, 16] show some overlap between LysoGb3 values of 
FD females and healthy individuals. While augmenting functional characterization of 
GLA mutations, LysoGb3 cannot replace a detailed clinical characterization using a 
multidisciplinary approach, family history, genetic testing and the phenotypic 
descriptions of the family mutation. Thus, more sensitive biomarkers will be needed 
to distinguish between the Later-Onset phenotype FD patients, particularly women, 
and healthy persons. 
LysoGb3 is not only a biomarker. It might also be involved in the FD pathology. 
LysoGb3 has been shown to promote Notch1-mediated inflammatory and fibrogenic 
response in podocytes potentially contributing to Fabry nephropathy [42]. LysoGb3 
treatment inhibited the proliferation and differentiation of fibroblasts into 
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myofibroblasts, reducing collagen synthesis and herewith compromising vascular 
remodeling [43]. It directly inhibited the α-Gal A activity and induced smooth muscle 
cell proliferation [14]. Administration of LysoGb3 stimulated the up-regulation of 
voltage-dependent Ca2+ channels in nociceptive neurons, suggesting that it may 
induce pain through direct actions on sensory neurons [44]. 
Several limitations merit consideration.  First, the number of our Later-Onset group 
patients was low. Second, the study was not designed to evaluate the ability of 
LysoGb3 to predict the development of major clinical events. Third, the study did not 
assess epigenetic phenomena, such as the influence of the degree of the random X-
chromosomal inactivation on LysoGb3 levels in females. Finally, for the use as a 
clinical biomarker, standardization of the technical methods and inter-laboratory 
testing is needed in order to compare LysoGb3 measurements among laboratories. 
In conclusion, the use of LysoGb3 as an additional laboratory biomarker appears to 
improve the detection and management of clinically relevant FD. LysoGb3 levels are 
associated with the important clinical sequelae of FD such as nephro-, 
cardiomyopathy and cerebrovascular disease, thus, LysoGb3 may represent the new 
concept of metabolic phenotype. LysoGb3 helps to stratify persons at risk and may 
provide guidance towards a more individualized treatment of patients. 
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